利拉鲁肽治疗新诊断2型糖尿病患者的有效性及安全性  

The effectiveness and safety of liraglutide in treatment of newly diagnosed type 2 diabetes mellitus

作　　者：黄倩[1] 刘婵[1] 黄福常[1] 张玲[1] 李佳芮[1] 王丹 骆雅静 王亚娜 HUANG Qian;LIU Chan;HUANG Fuchang(Department of Endocrinology, Central Hospital of Cangzhou City, Hebei, Cangzhou 061001 ,China)

机构地区：[1]河北省沧州市中心医院内分泌科

出　　处：《河北医药》2019年第12期1821-1824,共4页Hebei Medical Journal

摘　　要：目的探讨利拉鲁肽治疗新诊断2型糖尿病患者的有效性及安全性。方法选取2016年4月至2017年4月内分泌科住院的2型糖尿病患者,按照标准纳入患者40例,随机分为试验组和对照组,每组20例。对照组采用口服降糖药物或胰岛素治疗,试验组在此基础上加用利拉鲁肽。治疗6个月后观察试验组和对照组的治疗效果。结果试验组和对照组在进行利拉鲁肽治疗后,空腹血糖、餐后2 h血糖及糖化血红蛋白和治疗前比较均有显著下降(P<0.05),但试验组和对照组差异无统计学意义(P>0.05)。利拉鲁肽组治疗后体重、腹围、BMI值、血脂、总胆固醇指标较治疗前显著降低(P<0.05),且试验组和对照组间差异有统计学意义(P<0.05)。结论利拉鲁肽治疗新诊断2型糖尿病的降糖效果显著,可以降低患者体重,降低血脂、总胆固醇等指标,同时具有良好的安全性。Objective To investigate the effectiveness and safety of liraglutide in treatment of newly diagnosed type 2 diabetes mellitus.Methods Forty patients with type 2 diabetes mellitus who were diagnosed and treated in department of endocrinology from April 2016 to April 2017 were randomly divided into experimental group(n=40) and control group(n=40).The patients in control group were treated by oral hypoglycemics or insulin,however,the patients in experimental group,on the basis of control group, were treated by liraglutide.After 6-month treatment,the therapeutic effects were observed and compared between two groups.Results After treatment the levels of fasting blood glucose,postprandial 2 h blood glucose and glycated hemoglobin were significantly decreased in both groups, as compared with those before treatment(P<0.05),however,there were no significant differences between the two groups(P>0.05).After treatment,the body weight,abdominal circumference,BMI value,blood lipids,total cholesterol levels in experimental group were significantly decreased,as compared with those before treatment(P<0.05),moreover,there were significant differences between the two groups(P<0.05).Conclusion The liraglutide in treatment of newly diagnosed type 2 diabetes mellitus has significant hypoglycemic effects,which can reduce patient’s body weight,decrease blood lipids,total cholesterol and the other indexes,with good safety.

关 键 词：利拉鲁肽 胰岛素 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]